Previous Next

ARCHIVE

№3' 2013

THERAPY

International Medical Journal, Vol. 19., Iss. 3, 2013, P. 50−55.

THERAPEUTIC CORRECTION OF ATHEROGENIC DYSLIPIDEMIA AT METABOLIC SYNDROME

Kharkiv National Medical University

Abstract. Main information about modern classification of metabolic syndrome is presented. The questions of lipid metabolism disorders in metabolic syndrome are featured, it is emphasized that atherogenic dyslipidemia is considered a trigger mechanism of a cascade of metabolic disorders at metabolic syndrome. Biochemical and pathophysiological aspects of influence on the syndrome pathogenesis of main classes of lipoproteids are presented. The findings of the clinical investigation allowed to compare and classify main groups of hypolipidemic drugs. Based on the data of evidence based medicine in the context of cardiovascular risk main indications, contraindications and efficacy of main groups of hypolipidemic drugs at metabolic syndrome are discussed. Preliminary findings about clinical efficacy of new groups and prospects of development of hypolipidemic drugs combinations are reported.

Key words: metabolic syndrome, atherogenic dyslipidemia, hypolipidemic drugs.